Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

Harmine, DYRK1A Inhibitor

Harmine, DYRK1A Inhibitor

$29.00
A potent, selective and orally bioavailable DYRK1A inhibitor.
Catalog No. Unit Price Qty
M60241-5s 5 mg solid $29.00

Details

Product Information
Molecular Weight: 212.25
Formula: C13H12N2O
Purity: ≥98%
CAS#: 442-51-3
Solubility: DMSO up to 100 mM
Chemical Name: 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

Harmine is a potent, selective and orally bioavailable DYRK1A inhibitor with IC50 of 80 nM. It inhibits phosphorylation of tau directly by DYRK1A (IC50 ~700 nM). It has >10-fold selectivity over DYRK3 and DYRK2 (IC50 ~800 nM and 900 nM respectively. Harmine is also a unique regulator of PPARγ expression that acts by inhibiting the Wnt signalling pathway in a cell-specific manner. It attenuates inflammatory gene expression (TNFα, IL-1β, iNOS) and macrophage accumulation in adipose tissue. Administration of harmine (30 mg/kg) to obese db/db mice resulted in reduced blood glucose, free fatty acids, and triglyceride levels, delayed hyperglycemia, and improved insulin sensitivity. Being function as a new class of human beta cell mitogenic compound, by using three different mouse and human islet in vivo-based models, harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. The nuclear factors of activated T cells (NFAT) family of transcription factors are defined as likely mediators of human beta cell proliferation and differentiation.

How to Use:


In vitro: Harmine was used at 10 µM final concentration in various in vitro assays.
In vivo: Harmine was dosed orally to obese db/db mice at 30 mg/kg. Harmine was dosed by intraperitoneal injection at 10 mg/kg in mouse partial pancreatectomy model (PPX), Euglycemic human islet transplantation model and diabetic marginal mass human islet transplantation model.

Reference:

  • 1. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. (2007) Biochem J. 408(3):297-315.
  • 2. Waki H, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. (2007) Cell Metab. 5(5):357-70.
  • 3. Egusa H, et al. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells. (2011) Bone. 49(2):264-74. 
  • 4. Smith B, et al. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? (2012) ACS Chem Neurosci. 3(11):857-72.
  • 5. Wang P, at al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. (2015) Nat Med. In press. 


Harmine_spec.pdf     
Harmine_MSDS.pdf 

Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 212.25
Formula: C13H12N2O
Purity: ≥98%
CAS#: 442-51-3
Solubility: DMSO up to 100 mM
Chemical Name: 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

Harmine is a potent, selective and orally bioavailable DYRK1A inhibitor with IC50 of 80 nM. It inhibits phosphorylation of tau directly by DYRK1A (IC50 ~700 nM). It has >10-fold selectivity over DYRK3 and DYRK2 (IC50 ~800 nM and 900 nM respectively. Harmine is also a unique regulator of PPARγ expression that acts by inhibiting the Wnt signalling pathway in a cell-specific manner. It attenuates inflammatory gene expression (TNFα, IL-1β, iNOS) and macrophage accumulation in adipose tissue. Administration of harmine (30 mg/kg) to obese db/db mice resulted in reduced blood glucose, free fatty acids, and triglyceride levels, delayed hyperglycemia, and improved insulin sensitivity. Being function as a new class of human beta cell mitogenic compound, by using three different mouse and human islet in vivo-based models, harmine is able to induce beta cell proliferation, increase islet mass and improve glycemic control. The nuclear factors of activated T cells (NFAT) family of transcription factors are defined as likely mediators of human beta cell proliferation and differentiation.

How to Use:


In vitro: Harmine was used at 10 µM final concentration in various in vitro assays.
In vivo: Harmine was dosed orally to obese db/db mice at 30 mg/kg. Harmine was dosed by intraperitoneal injection at 10 mg/kg in mouse partial pancreatectomy model (PPX), Euglycemic human islet transplantation model and diabetic marginal mass human islet transplantation model.

Reference:

  • 1. Bain J, et al. The selectivity of protein kinase inhibitors: a further update. (2007) Biochem J. 408(3):297-315.
  • 2. Waki H, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. (2007) Cell Metab. 5(5):357-70.
  • 3. Egusa H, et al. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells. (2011) Bone. 49(2):264-74. 
  • 4. Smith B, et al. Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's? (2012) ACS Chem Neurosci. 3(11):857-72.
  • 5. Wang P, at al. A high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication. (2015) Nat Med. In press. 


Harmine_spec.pdf     
Harmine_MSDS.pdf 

Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: